Vijaya Diagnostic Centre Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Vijaya Diagnostic Centre Ltd filed with BSE on 10 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Vijaya Diagnostic reported consolidated revenue of approximately Rs 231 crore for Q1 FY27, up 22.8% year-on-year, driven by 16.5% volume growth. EBITDA grew 34% to Rs 98 crore with margin at 42.7%, and profit after tax rose 37.6% to Rs 53 crore. Management detailed network expansion including two new hub centres in Bengaluru and Gachibowli, and outlined plans to commission 9 more hub centres and 10-12 spoke centres with capex of Rs 190-195 crore.
Numbers mentioned
Revenue: Rs 231 crores (Q1 FY27)
p. 4
“The consolidated revenue for current quarter stood at ~Rs. 231 crores reflecting a strong revenue growth rate of 22.8% year-on-year, and this strong revenue growth was again driven by test volume growth of 16.5% year-on-year.”
Narasimha Raju, page 4 of the filed PDF · View the filing
EBITDA: INR98 crores (Q1 FY27)
p. 4
“EBITDA for the current quarter stood at INR98 crores as compared to INR74 crores in the corresponding quarter in the previous year reflecting a year-on-year growth rate of 34%.”
Narasimha Raju, page 4 of the filed PDF · View the filing
EBITDA margin: 42.7% (Q1 FY27)
p. 4
“The EBITDA margin stood healthy at 42.7% in the current quarter with an improvement of 360 basis points year-on-year.”
Narasimha Raju, page 4 of the filed PDF · View the filing
Profit after tax: INR53 crores (Q1 FY27)
p. 4
“The profit after tax for the current quarter stood at INR53 crores reflecting a growth of 37.6%.”
Narasimha Raju, page 4 of the filed PDF · View the filing
PAT margin: 23% (Q1 FY27)
p. 4
“And the PAT margin also stood healthy at 23%.”
Narasimha Raju, page 4 of the filed PDF · View the filing
Revenue per test: INR503 (Q1 FY27)
p. 4
“the revenue per test and revenue per footfall stood at INR503 and INR1,860, respectively, during the current quarter.”
Narasimha Raju, page 4 of the filed PDF · View the filing
Hyderabad revenue growth: 17% (Q1 FY27)
p. 4
“Hyderabad continued to outperform, maintaining its strong growth momentum at 17% year-onyear revenue growth.”
Narasimha Raju, page 4 of the filed PDF · View the filing
Pune revenue growth: 18% (Q1 FY27)
p. 4
“Pune also delivered 18% growth year-on-year.”
Narasimha Raju, page 4 of the filed PDF · View the filing
Cash position: approximately INR330 crores
p. 5
“We continue to maintain a strong balance sheet with a surplus cash position of approximately INR330 crores, consistent cash PAT generation of close to 26% to 27%, and a healthy return ratios.”
Narasimha Raju, page 5 of the filed PDF · View the filing
Total centres: 166 (Q1 FY27)
p. 5
“So in the total of 166 centres, we have 51 hubs and 115 spokes with approximately 26 processing units.”
Suprita Reddy, page 5 of the filed PDF · View the filing
Mature centre growth: 16% (Q1 FY27)
p. 13
“So, the mature centres, you know, grew at 16% and the new centres, the revenue contribution from them was 6% to 6.5% for the quarter, year-on-year.”
Dhiren Gala, page 13 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Capex — INR190 crores to INR195 crores · FY27
stated firmly by Narasimha Raju
p. 4
“Overall, we expect our capex to be approximately INR190 crores to INR195”
Narasimha Raju, page 4 of the filed PDF · View the filing
Hub centre commissioning — 9 hub centres and 10 to 12 spoke centres · next 12 months
stated firmly by Narasimha Raju
p. 6
“in the next 12 months we're planning to add close to 9 hub centres and 10 to 12 spoke centres, out of which we already added 2 hub centres as of now.”
Narasimha Raju, page 6 of the filed PDF · View the filing
EBITDA margin — above 40%
stated conditionally by Narasimha Raju
p. 7
“So even if you get like a 40% to 45%, even if there's a drag from the Future expansion, another one, one and a half percent, we are fairly confident of achieving the above 40% EBITDA margin.”
Narasimha Raju, page 7 of the filed PDF · View the filing
Revenue growth — high double digit · FY27
stated conditionally by Narasimha Raju
p. 14
“We're fairly confident of giving high double digit growth for FY27.”
Narasimha Raju, page 14 of the filed PDF · View the filing
Revenue growth — 15% · 3 to 5 year
stated as an aspiration by Narasimha Raju
p. 14
“Like a 3 to 5 year growth on a sustainable basis we believe achieving 15% is easy.”
Narasimha Raju, page 14 of the filed PDF · View the filing
Land acquisition in Andhra Pradesh — INR8 crores to INR10 crores
stated firmly by Narasimha Raju
p. 4
“In addition, we intend to acquire land in one of Andhra Pradesh's key medical hub for setting up another hub centre for future expansion plans with an estimated investment of INR8 crores to”
Narasimha Raju, page 4 of the filed PDF · View the filing
Hub centre expansion in Pune, Bangalore, Kolkata — 15 hub centres
stated firmly by Narasimha Raju
p. 14
“So 9 plus 6, we're going to add like 15 hub centres across these 3 new metro markets where we are planning to go deeper.”
Narasimha Raju, page 14 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said operating leverage from existing clusters is helping maintain healthy margins despite new hub additions.
Answered by Narasimha Raju
Asked by Abdulkader: Whether the company would guide for around 40% EBITDA margin given the expansion plans.
p. 7
“Yes, Abdul. The existing clusters have been growing at a very good rate, the operating leverage is being played out.”
Narasimha Raju, page 7 of the filed PDF · View the filing
Management said no margin dip is expected since fixed costs are already absorbed and further pathology revenue flows directly to EBITDA.
Answered by Narasimha Raju
Asked by Anshul Agrawal: Whether margins would dip in hubs commissioned in FY26 as pathology revenue scales up.
p. 7
“We don't foresee any dip from these hub centres because 60% to 70% of our cost is coming from the fixed cost base.”
Narasimha Raju, page 7 of the filed PDF · View the filing
Management said Bangalore's competition is fragmented into small local chains rather than large single brands, unlike other markets.
Answered by Suprita Reddy
Asked by Alankar Garude: How the competitive landscape in Bangalore compares to other markets after a year of operations.
p. 9
“You've not seen large brands grow in Bangalore where a single brand has about 30 to 40 centres.”
Suprita Reddy, page 9 of the filed PDF · View the filing
Management said the company has consistently outperformed industry growth due to its B2C focus and high-quality reporting.
Answered by Narasimha Raju
Asked by Abin Benny: How much of the growth is from market share gains versus industry growth.
p. 11
“We used to give at least like 4% to 5% higher growth than the industry.”
Narasimha Raju, page 11 of the filed PDF · View the filing
Management said the burn from hubs not yet at breakeven was roughly 0.5% of revenue, amounting to less than Rs 1 crore.
Answered by Dhiren Gala
Asked by Siddhant K: What was the absolute EBITDA loss from new centres in the quarter.
p. 13
“the burn is roughly about 0.5% of our top line.”
Dhiren Gala, page 13 of the filed PDF · View the filing
Management attributed this to lower B2B exposure than peers and higher tests per patient driving higher realization.
Answered by Narasimha Raju
Asked by Amey Chalke: Why margins are expanding even as pathology's share of revenue grows, despite pathology typically having lower margins.
p. 15
“It's close to like a 3.7 test that we do for every patient who is walking into our network as compared to 2.5 to 3 tests that a typical pathology chain does.”
Narasimha Raju, page 15 of the filed PDF · View the filing
Management said the last price hike was in June 2025 restricted to Hyderabad, and future pricing strategy would be reassessed after Q2 and Q3.
Answered by Dhiren Gala
Asked by Jyothish Vijayan: Whether the company has taken any price hikes over the last two years and its pricing strategy going forward.
p. 15
“The last price hike which we had taken was in the month of June 2025 where it was restricted to Hyderabad across select tests.”
Dhiren Gala, page 15 of the filed PDF · View the filing
Management said competitors are deploying capital outside Hyderabad due to Vijaya's dominant market share there.
Answered by Dhiren Gala
Asked by Jyothish Vijayan: Whether competitive intensity has changed in Telangana and Karnataka.
p. 15
“the second and the third best diagnostic centre are smartly deploying their capital outside of Hyderabad because Vijaya has already greater market share here.”
Dhiren Gala, page 15 of the filed PDF · View the filing
Risks flagged
Pune market required more time to develop than initially guided due to being a new, unfamiliar market.
p. 9
“So, initially when we entered Maharashtra with the Pune acquisition, we said we needed a little more time than the guidance that we had given because it is a new market and we are trying to understand the needs of that localized market.”
Suprita Reddy, page 9 of the filed PDF · View the filing
Uncertainty around compliance and regulatory requirements limits ability to monetize accumulated healthcare data.
p. 13
“But today we do not know in terms of compliance on what can be done, cannot be done.”
Suprita Reddy, page 13 of the filed PDF · View the filing
Some new hubs have not yet reached breakeven, causing a modest drag on EBITDA.
p. 13
“the burn is roughly about 0.5% of our top line.”
Dhiren Gala, page 13 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.